Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible

Drug Metabolism and Disposition

Volumn 32, Issue 1, 2004, Pages 105-112

  Stresser, David M ^a,b   Broudy, Marc I ^a   Ho, Thuy ^a   Cargill, Catherine E ^a   Blanchard, Andrew P ^a   Sharma, Raman ^a   Dandeneau, Andre A ^a   Goodwin, Joseph J ^a   Turner, Stephanie D ^a   Erve, John C L ^a   Patten, Christopher J ^a   Dehal, Shangara S ^a   Crespi, Charles L ^a  

^a Discovery Labware   (United States)

^b BD Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 O [5 (2 AMINO 1,3,4 TRIAZOLYL)THIOACETYL]DIHYDROMUTILIN; 7 BENZYLOXY 4 TRIFLUOROMETHYLCOUMARIN; AMFEBUTAMONE; AZAMULIN; BENZYLOXYRESORUFIN; COUMARIN DERIVATIVE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 4F12; CYTOCHROME P450 4F2; MIDAZOLAM; PACLITAXEL; PHENACETIN; PLEUROMUTILIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESORUFIN DERIVATIVE; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CATALYSIS; CHEMICAL ANALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE TIME EFFECT RELATION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STABILITY; DRUG STORAGE; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; INSECT CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ANTI-INFECTIVE AGENTS; BRIDGED COMPOUNDS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLUOROMETRY; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; NADP; PLEUROTUS; SOLUBILITY; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY; TRIAZOLES; XENOBIOTICS;

ANIMALIA; INSECTA; STAPHYLOCOCCUS PHAGE 3A;

EID: 1642498315     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.1.105     Document Type: Article

References (40)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Ballard SA, Lodola A, and Tarbit MH (1988) A comparative study of I-substituted imidazole and 1,2,4-triazole antifungal compounds as inhibitors of testosterone hydroxylations catalysed by mouse hepatic microsomal cytochromes P-450. Biochem Pharmacol 37:4643-4651.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) Perspective: the conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
4. Bourrie M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
5. Busby WF Jr, Ackermann JM, and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249.
6. Chang TKH, Gonzalez FJ, and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and dicethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-443.
7. Chiba M, Jin L, Neway W, Vacca JP, Tata JR, Chapman K, and Lin JH (2001a) P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency and P450 binding spectra. Drug Metab Dispos 29:1-3.
8. Chiba M, Tang C, Neway WE, Williams TM, Desolms SJ, Dinsmore CJ, Wai JS, and Lin JH (2001b) P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency and P450 binding spectra in human liver microsomes. Biochem Pharmacol 62:773-776.
9. Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM, Carlesso N, Scadden DT, Rettie AE, and Soberman RJ (2001) Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276:38166-38172
10. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202.
11. Clarke SE (2000) Open discussion, 7th EUFEPS Conference on Optimising Drug Development: Strategies to Assess Drug Metabolism/Transport Interaction Potential-Towards a Consensus. November 13-15, 2000, Basel, Switzerland.
12. Crespi CL, Chang TKH, and Waxman DJ (1998) Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection. Methods Mol Biol 107:163-167.
13. Crespi CL, Miller VP, and Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190.
14. Crespi CL, Miller VP, and Stresser DM (2002) Design and application of fluorometric assays for human cytochrome P450 inhibition. Methods Enzymol 357:276-284.
15. De Groene EM, Nijmeijer SM, Horbach GJ, and Witkamp RF (1995) Tiamulin inhibits human CYP3A4 activity in an NIH/3T3 cell line stably expressing CYP3A4 cDNA. Biochem Pharmacol 50:771-773.
16. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
17. Erve JCL, Dandeneau AL, Stresser DM, and Crespi CL (2000) Metabolic stability of CYP isoform selective inhibitors in the presence of human liver microsomes, in 13th International Symposium on Microsomes and Drug Oxidations, July 10-14, 2000, Stresa, Italy. Abstract no. 237, Edizioni MAF Servizi, Torino, Italy.
18. Franklin MR (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559-573.
19. Gao F, Johnson DL, Ekins S, Janiszewski J, Kelly KG, Meyer RD, and West M (2002) Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6 and CYP3A4 in vitro using a single point IC50. J Biomol Screen 7:373-382.
20. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371.
21. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304.
22. Kavanagh F, Hervey A, and Robbins WJ (1951) Antibiotic substances from basidomycetes. VIII. Pleurotus mutilus (Fr.) Sacc. & Pleurotus passeckerianus Pilat. Proc Natl Acad Sci USA 37:570-574.
23. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
24. Maenpaa J, Hall SD, Ring BJ, Strom SC, and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
25. Matsumoto S, Hirama T, Matsubara T, Nagata K, and Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:1240-1245.
26. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, and Maurel P (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 6:752-758.
27. Miller VP, Stocker PJ, Code EL, Penman BW, and Crespi CL (1997) Characterization of a comprehensive panel of human cDNA-expressed xenobiotic metabolizing enzymes in microsomes prepared from baculovirus infected insect cells (Supersomes™), in Proceedings of the North American ISSX Meeting, Hilton Head, SC. October 26-30, 1997. Abstr. No. 324.
28. Miners J and McKinnon R (2000) CYP1A, in Metabolic Drug Interactions (Levy R, Thummel K, Trager W, Hansten P, and Eichelbaum M, eds) pp. 61-73, Lippincott, Williams & Wilkins, Philadelphia
29. Moody GC, Griffin SJ, Mather AN, McGinnity DF, and Riley RJ (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29:53-75.
30. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
31. Paine MF, Schmiedlin-Ren P, and Watkins PB (1999) Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 27:360-364.
32. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, and Shou M (2000) Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 30:327-343.
33. Schenkman JB, Sligar SG, and Cinti DL (1981) Substrate interaction with cytochrome P-450. Pharmacol Ther 12:43-71.
34. Silverman RB (1996) Mechanism-based enzyme inactivators, in Contemporary Enzyme Kinetics and Mechanism, 2nd ed (Purich DL, ed) pp. 291-334, Academic Press, San Diego.
35. Stresser DM, Turner SD, Blanchard AP, Miller VP, and Crespi CL (2002) Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos 30:845-852.
36. Stresser DM, Turner SD, Blanchard AP, Miller VP, Erve JCL, Dandeneau AC, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
37. Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, and Greenblatt DJ (2002) Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441-1445.
38. Witkamp RF, Nijmeijer SM, and van Miert AS (1996) Cytochrome P-450 complex formation in rat liver by the antibiotic tiamulin. Antimicrob Agents Chemother 40:50-54.
39. Wrighton SA and Thummel KE (2000) CYP3A, in Metabolic Drug Interactions (Levy R, Thummel K, Trager W, Hansten P, and Eichelbaum M, eds) pp 115-133. Lippincott, Williams & Wilkins, Philadelphia.
40. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, and Sellers EM (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314-318.